TITLE:
Management of Testicular Cancers in Brazzaville
AUTHORS:
Roland Bertile Banga-Mouss, Yanick Dimi Nyanga, Brice Nkoua Epala, Armel Melvin Atipo Ondongo, Steve Aristid Ondziel-Opara, Eliane Ndounga, Alexis Bolenga, Louis Constant Mbele Mantsouaka, Judith Nsonde Malanda, Aanani Séverin Wencesl Odzébé, Prosper Alain Bouya
KEYWORDS:
Testicular Cancer, Germ Cell Tumor, Cisplatin, Testicular Lymphoma, Testicular Adenocarcinoma
JOURNAL NAME:
Open Journal of Urology,
Vol.14 No.5,
May
21,
2024
ABSTRACT: Introduction: Testicular cancer accounts for 5% of urological tumors, predominantly affecting young men. The aim of our study was to report the diagnostic and evolutionary aspects of testicular cancer cases treated in our center. Patients and Methods: A retrospective study conducted over a 15-year period involving 12 patients treated for testicular cancer at the University Hospital of Brazzaville. Results: The median age was 31 years (range 11 to 49 years), with a median consultation delay of 10.6 months (range 3 to 27 months). Scrotal mass was the most common reason for consultation. Cancer was bilateral in two patients. Two patients were admitted with metastatic disease. Histopathological examination favored germ cell tumors in 7 cases, two cases of non-Hodgkin’s malignant lymphoma, and one case of epididymo-testicular adenocarcinoma. Adjuvant chemotherapy resulted in complete remission in patients with germ cell tumors. However, neoadjuvant chemotherapy was not effective in patients admitted with advanced-stage disease. Conclusion: Testicular cancer is a rare condition that is curable in the majority of cases, but its management is often complicated in our setting due to delayed diagnosis caused by taboos surrounding genital organ pathologies.